Reduction of pituitary size by the somatostatin analogue SMS 201-995 in a patient with an islet cell tumour secreting growth hormone releasing factor.
Acromegaly is rarely caused by the ectopic secretion of growth hormone releasing factor (GRF) from peripheral neuroendocrine tumours. We evaluated the ability of a recently developed somatostatin analogue (SMS 201-995, Sandoz) to reduce hormone levels and pituitary size in a young woman with acromegaly and Zollinger-Ellison syndrome secondary to a metastatic pancreatic islet cell tumour secreting GRF and gastrin. Gastrin, GRF, and growth hormone (GH) levels declined dramatically following the initiation of therapy with the analogue by continuous iv infusion. Although intermittent sc therapy was not effective in suppressing hormone levels, continuous sc infusion of SMS 201-995 has provided good control of both GRF and GH levels for nine months. Moreover, treatment with SMS 201-995 was associated with a substantial reduction in pituitary enlargement and an improvement in her gastric symptoms. Continuous sc infusion of SMS 201-995 may be useful in treating enlarged pituitaries resistant to other modes of therapy.
D000172:Acromegaly / Q000188:drug therapy* / Q000209:etiology; D007516:Adenoma, Islet Cell / Q000150:complications / Q000378:metabolism*; D000328:Adult; D005260:Female; D005755:Gastrins / Q000097:blood; D013006:Growth Hormone / Q000097:blood; D013007:Growth Hormone-Releasing Hormone / Q000378:metabolism*; D006801:Humans; D015282:Octreotide; D010190:Pancreatic Neoplasms / Q000150:complications / Q000378:metabolism*; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D015043:Zollinger-Ellison Syndrome / Q000209:etiology
D005755:Gastrins; D013004:Somatostatin; D013006:Growth Hormone; D013007:Growth Hormone-Releasing Hormone; D015282:Octreotide